ACTINIUM PHARMACEUTICALS, INC. Share-based Payment Arrangement, Expense
ACTINIUM PHARMACEUTICALS, INC. (ATNM) reported Share-based Payment Arrangement, Expense of $6.00 thousand for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-31.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AllocatedShareBasedCompensationExpense · last filed 2023-03-31
- ACTINIUM PHARMACEUTICALS, INC. share-based payment arrangement, expense for the quarter ending 2021-06-30 was $3.20M.
- ACTINIUM PHARMACEUTICALS, INC. share-based payment arrangement, expense for the quarter ending 2021-03-31 was $400.00K, a 0.00% change year-over-year.
- ACTINIUM PHARMACEUTICALS, INC. share-based payment arrangement, expense for the quarter ending 2020-03-31 was $400.00K.
- ACTINIUM PHARMACEUTICALS, INC. share-based payment arrangement, expense for the quarter ending 2016-12-31 was -$2.69M, a 484.29% decline year-over-year.
- ACTINIUM PHARMACEUTICALS, INC. share-based payment arrangement, expense for fiscal 2022 was $6.00K, a 62.50% decline from fiscal 2021.
- ACTINIUM PHARMACEUTICALS, INC. share-based payment arrangement, expense for fiscal 2021 was $16.00K.
- ACTINIUM PHARMACEUTICALS, INC. share-based payment arrangement, expense for fiscal 2019 was $8.00K, a 75.76% decline from fiscal 2018.
- ACTINIUM PHARMACEUTICALS, INC. share-based payment arrangement, expense for fiscal 2018 was $33.00K, a 230.00% increase from fiscal 2017.
| Period end | Share-based Payment Arrangement, Expense 3 month | Share-based Payment Arrangement, Expense 3 month as first filed | Share-based Payment Arrangement, Expense 6 month | Share-based Payment Arrangement, Expense 6 month as first filed | Share-based Payment Arrangement, Expense 9 month | Share-based Payment Arrangement, Expense 9 month as first filed | Share-based Payment Arrangement, Expense 12 month |
|---|---|---|---|---|---|---|---|
| 2022-12-31 | $6.00K 10-K · filed 2023-03-31 | ||||||
| 2021-12-31 | $16.00K 10-K · filed 2023-03-31 | ||||||
| 2021-06-30 | $3.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-30 | $3.60M 10-Q · filed 2021-07-30 | |||||
| 2021-03-31 | $400.00K 10-Q · filed 2021-05-14 | ||||||
| 2020-03-31 | $400.00K 10-Q · filed 2021-05-14 | ||||||
| 2019-12-31 | $8.00K 10-K · filed 2020-05-08 | ||||||
| 2018-12-31 | $33.00K 10-K · filed 2020-05-08 | ||||||
| 2017-12-31 | $10.00K 10-K · filed 2019-03-15 | ||||||
| 2016-12-31 | -$2.69M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-15 | -$1.69M derived: sum of 2 quarters · filed 2019-03-15 | -$790.00K derived: sum of 3 quarters · filed 2019-03-15 | $10.00K 10-K · filed 2019-03-15 | |||
| 2016-09-30 | $1.00M 10-Q · filed 2016-10-28 | $1.90M derived: sum of 2 quarters · filed 2016-10-28 | $2.70M 10-Q · filed 2016-10-28 | $3.40M derived: sum of 4 quarters · filed 2016-10-28 | |||
| 2016-06-30 | $900.00K 10-Q · filed 2016-07-29 | $1.70M 10-Q · filed 2016-07-29 | $2.40M derived: sum of 3 quarters · filed 2016-07-29 | $3.20M derived: sum of 4 quarters · filed 2016-10-28 | |||
| 2016-03-31 | $800.00K 10-Q · filed 2016-05-10 | $1.50M derived: sum of 2 quarters · filed 2016-05-10 | $2.30M derived: sum of 3 quarters · filed 2016-10-28 | $3.20M derived: sum of 4 quarters · filed 2016-10-28 | |||
| 2015-12-31 | $700.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-11 | $1.50M derived: sum of 2 quarters · filed 2016-10-28 | $2.40M derived: sum of 3 quarters · filed 2016-10-28 | $3.40M 10-K · filed 2016-03-11 | |||
| 2015-09-30 | $800.00K 10-Q · filed 2016-10-28 | $1.70M derived: sum of 2 quarters · filed 2016-10-28 | $2.70M 10-Q · filed 2016-10-28 | $3.50M derived: sum of 4 quarters · filed 2016-10-28 | |||
| 2015-06-30 | $900.00K 10-Q · filed 2016-07-29 | $1.90M 10-Q · filed 2016-07-29 | $2.70M derived: sum of 3 quarters · filed 2016-07-29 | $3.40M derived: sum of 4 quarters · filed 2016-07-29 | |||
| 2015-03-31 | $1.00M 10-Q · filed 2016-05-10 | $1.80M derived: sum of 2 quarters · filed 2016-05-10 | $2.50M derived: sum of 3 quarters · filed 2016-05-10 | $3.10M derived: sum of 4 quarters · filed 2016-05-10 | |||
| 2014-12-31 | $800.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-11 | $1.50M derived: sum of 2 quarters · filed 2016-03-11 | $2.10M derived: sum of 3 quarters · filed 2016-03-11 | $2.40M 10-K · filed 2016-03-11 | |||
| 2014-09-30 | $700.00K 10-Q · filed 2015-10-30 | $734.80K 10-Q · filed 2014-10-31 | $1.30M derived: sum of 2 quarters · filed 2015-10-30 | $1.60M 10-Q · filed 2015-10-30 | $1.62M 10-Q · filed 2014-10-31 | $1.62M derived: sum of 4 quarters · filed 2016-03-11 | |
| 2014-06-30 | $600.00K 10-Q · filed 2015-08-07 | $607.79K 10-Q · filed 2014-08-12 | $900.00K 10-Q · filed 2015-08-07 | $889.20K 10-Q · filed 2014-08-12 | $915.63K derived: sum of 3 quarters · filed 2016-03-11 | $1.01M derived: sum of 4 quarters · filed 2016-03-11 | |
| 2014-03-31 | $300.00K 10-Q · filed 2015-05-08 | $281.40K 10-Q · filed 2014-05-12 | $315.63K derived: sum of 2 quarters · filed 2016-03-11 | $411.60K derived: sum of 3 quarters · filed 2016-03-11 | $505.80K derived: sum of 4 quarters · filed 2016-03-11 | ||
| 2013-12-31 | $15.63K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-11 | $111.60K derived: sum of 2 quarters · filed 2016-03-11 | $205.80K derived: sum of 3 quarters · filed 2016-03-11 | $300.00K 10-K · filed 2016-03-11 | |||
| 2013-09-30 | $95.97K 10-Q · filed 2014-10-31 | $190.17K derived: sum of 2 quarters · filed 2014-10-31 | $284.37K 10-Q · filed 2014-10-31 | ||||
| 2013-06-30 | $94.20K 10-Q · filed 2014-08-12 | $188.40K 10-Q · filed 2014-08-12 | |||||
| 2013-03-31 | $94.20K 10-Q · filed 2013-08-13 | $188.40K 10-Q · filed 2013-08-13 | |||||
| 2012-12-31 | $200.00K 10-K · filed 2014-02-28 | ||||||
| 2012-09-30 | $72.10K 10-Q · filed 2013-11-14 | ||||||
| 2012-03-31 | $40.41K 10-Q · filed 2013-08-13 | $199.99K 10-Q · filed 2013-05-15 | $240.40K 10-Q · filed 2013-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 |